# Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib

> **NCT07486648** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanxi Province Cancer Hospital** · enrollment: 53 (estimated)

## Conditions studied

- Lung Cancer (NSCLC)
- Lung Cancer (Non-Small Cell)
- Advanced Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Capivasertib in combination with Osimertinib

## Key facts

- **NCT ID:** NCT07486648
- **Lead sponsor:** Shanxi Province Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2028-10-15
- **Final completion:** 2028-12-31
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07486648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07486648, "Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07486648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*